[关键词]
[摘要]
目的 分析重组人干扰素α-2b联合恩替卡韦对慢性乙型肝炎患者免疫功能的影响。方法 选取2016年1月-2018年1月济源市人民医院收治的慢性乙型肝炎患者95例为研究对象,根据入院顺序随机将其分为对照组和观察组,对照组49例患者给予恩替卡韦进行治疗,观察组46例患者给予重组人干扰素α-2b联合恩替卡韦进行治疗,两组患者均治疗3个月。对比两组患者的临床疗效、免疫功能变化及不良反应情况。结果 观察组治疗总有效率为89.13%,对照组治疗总有效率为77.55%,观察组显著高于对照组(P<0.05)。治疗前,两组患者的CD4+、CD8+、CD4+/CD8+、C3、C4水平均无统计学差异;治疗后,对照组CD4+、CD8+、CD4+/CD8+水平与治疗前比较差异不显著;观察组患者的CD4+、CD4+/CD8+水平均显著升高,CD8+水平显著降低(P<0.05);治疗后,两组C3、C4水平均显著高于治疗前(P<0.05);且观察组患者的C3、C4水平均显著高于对照组(P<0.05)。观察组不良反应总发生率为23.91%,与对照组不良反应总发生率24.49%比较,差异无统计学差异。结论 重组人干扰素α-2b联合恩替卡韦治疗慢性乙型肝炎的效果显著,该方法可有效改善患者的免疫功能、且不良反应未增加,临床应用价值较高。
[Key word]
[Abstract]
Objective To analyze the effect of pegylated interferon alfa-2b plus entecavir on immune function in patients with chronic hepatitis B.Methods We selected 95 patients with chronic hepatitis B treated in our hospital between January 2016 and January 2018 as subjects. According to the order of admission, they were randomly divided into a control group of 49 patients (treated with entecavir) and a study group of 46 patients (treated with pegylated interferon alfa-2b plus entecavir). The treatment effect of the two groups of patients was compared.Results The total effective rate of treatment in the study group was (89.13%) significantly higher than that of the control group (77.55%) (P<0.05). Before treatment, there was no significant difference in the levels of CD4+, CD8+, CD4+/CD8+, C3, and C4 between the two groups. After treatment, the levels of CD4+, CD8+, and CD4+/CD8+ in the study group were significantly lower than those in the treatment group (P<0.05); C3 and C4 levels in study group were significantly lower than before treatment and control group (P<0.05). The incidence of adverse reactions in the study group was 23.91%, and 24.49% in the control group was not statistically different.Conclusions The effect of pegylated interferon alfa-2b combined with entecavir in the treatment of chronic hepatitis B is significant. This method can effectively improve the patient's immune function and does not increase the adverse reactions. The clinical application value is high.
[中图分类号]
[基金项目]